

Table 58. Reason Therapy Was Extended Beyond 12 Months: Reporting Areas, 2013¹

| Reporting area | Total cases with therapy extended ^{2,3} | Reasons therapy was extended | | | | | | | | | | | |
|----------------------|--------------------------------------------------|------------------------------|--------------|---------------|---------------|--------------|---------------|-------------------|--------------|----------------------|---------------|------------|---------------|
| | | Rifampin resistant | | Adverse event | | Nonadherence | | Treatment failure | | Clinically indicated | | Other | |
| | | No. | (%) | No. | (%) | No. | (%) | No. | (%) | No. | (%) | No. | (%) |
| United States | 798 | 59 | (7.4) | 146 | (18.3) | 100 | (12.5) | 10 | (1.3) | 319 | (40.0) | 273 | (34.2) |
| Alabama | 4 | 0 | (0) | 0 | (0) | 1 | (25.0) | 0 | (0) | 2 | (50.0) | 1 | (25.0) |
| Alaska | 5 | 0 | (0) | 0 | (0) | 3 | (60.0) | 0 | (0) | 2 | (40.0) | 2 | (40.0) |
| Arizona | 22 | 1 | (4.5) | 4 | (18.2) | 5 | (22.7) | 1 | (4.5) | 13 | (59.1) | 5 | (22.7) |
| Arkansas | 6 | 0 | (0) | 1 | (16.7) | 2 | (33.3) | 1 | (16.7) | 1 | (16.7) | 1 | (16.7) |
| California | 192 | 17 | (8.9) | 57 | (29.7) | 19 | (9.9) | 0 | (0) | 86 | (44.8) | 51 | (26.6) |
| Colorado | 5 | 0 | (0) | 1 | (20.0) | 0 | (0) | 0 | (0) | 3 | (60.0) | 1 | (20.0) |
| Connecticut | 6 | 1 | (16.7) | 3 | (50.0) | 0 | (0) | 0 | (0) | 3 | (50.0) | 3 | (50.0) |
| Delaware | 1 | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (100.0) |
| District of Columbia | 8 | 1 | (12.5) | 0 | (0) | 3 | (37.5) | 0 | (0) | 3 | (37.5) | 3 | (37.5) |
| Florida | 45 | 6 | (13.3) | 4 | (8.9) | 7 | (15.6) | 0 | (0) | 21 | (46.7) | 8 | (17.8) |
| Georgia | 24 | 1 | (4.2) | 1 | (4.2) | 3 | (12.5) | 0 | (0) | 6 | (25.0) | 13 | (54.2) |
| Hawaii | 14 | 0 | (0) | 3 | (21.4) | 1 | (7.1) | 0 | (0) | 3 | (21.4) | 9 | (64.3) |
| Idaho | 2 | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (50.0) | 1 | (50.0) |
| Illinois | 24 | 1 | (4.2) | 4 | (16.7) | 3 | (12.5) | 0 | (0) | 7 | (29.2) | 10 | (41.7) |
| Indiana | 5 | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 4 | (80.0) | 1 | (20.0) |
| Iowa | 4 | 0 | (0) | 0 | (0) | 1 | (25.0) | 0 | (0) | 0 | (0) | 3 | (75.0) |
| Kansas | 0 | 0 | ... | 0 | ... | 0 | ... | 0 | ... | 0 | ... | 0 | ... |
| Kentucky | 4 | 0 | (0) | 1 | (25.0) | 1 | (25.0) | 0 | (0) | 1 | (25.0) | 1 | (25.0) |
| Louisiana | 20 | 0 | (0) | 1 | (5.0) | 1 | (5.0) | 1 | (5.0) | 3 | (15.0) | 14 | (70.0) |
| Maine | 1 | 0 | (0) | 0 | (0) | 1 | (100.0) | 0 | (0) | 0 | (0) | 0 | (0) |
| Maryland | 20 | 1 | (5.0) | 2 | (10.0) | 1 | (5.0) | 0 | (0) | 9 | (45.0) | 9 | (45.0) |
| Massachusetts | 20 | 2 | (10.0) | 1 | (5.0) | 0 | (0) | 0 | (0) | 8 | (40.0) | 9 | (45.0) |
| Michigan | 5 | 0 | (0) | 0 | (0) | 1 | (20.0) | 0 | (0) | 1 | (20.0) | 3 | (60.0) |
| Minnesota | 10 | 0 | (0) | 3 | (30.0) | 0 | (0) | 0 | (0) | 7 | (70.0) | 0 | (0) |
| Mississippi | 5 | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 5 | (100.0) |
| Missouri | 4 | 0 | (0) | 1 | (25.0) | 0 | (0) | 0 | (0) | 0 | (0) | 3 | (75.0) |
| Montana | 0 | 0 | ... | 0 | ... | 0 | ... | 0 | ... | 0 | ... | 0 | ... |
| Nebraska | 0 | 0 | ... | 0 | ... | 0 | ... | 0 | ... | 0 | ... | 0 | ... |
| Nevada | 4 | 1 | (25.0) | 1 | (25.0) | 0 | (0) | 0 | (0) | 2 | (50.0) | 0 | (0) |
| New Hampshire | 1 | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (100.0) |
| New Jersey | 31 | 3 | (9.7) | 8 | (25.8) | 3 | (9.7) | 0 | (0) | 13 | (41.9) | 9 | (29.0) |
| New Mexico | 2 | 0 | (0) | 1 | (50.0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (50.0) |

Table 58. (Con't) Reason Therapy Was Extended Beyond 12 Months: Reporting Areas, 2013¹

| Reporting area | Total cases with therapy extended ^{2,3} | Reasons therapy was extended | | | | | | | | | | | |
|----------------------------------------|--------------------------------------------------|------------------------------|--------|---------------|--------|--------------|---------|-------------------|--------|----------------------|---------|-------|---------|
| | | Rifampin resistant | | Adverse event | | Nonadherence | | Treatment failure | | Clinically indicated | | Other | |
| | | No. | (%) | No. | (%) | No. | (%) | No. | (%) | No. | (%) | No. | (%) |
| New York State ⁴ | 31 | 0 | (0) | 5 | (16.1) | 4 | (12.9) | 0 | (0) | 8 | (25.8) | 16 | (51.6) |
| New York City | 26 | 2 | (7.7) | 4 | (15.4) | 2 | (7.7) | 2 | (7.7) | 7 | (26.9) | 9 | (34.6) |
| North Carolina | 12 | 4 | (33.3) | 2 | (16.7) | 3 | (25.0) | 0 | (0) | 1 | (8.3) | 7 | (58.3) |
| North Dakota | 2 | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 2 | (100.0) |
| Ohio | 20 | 3 | (15.0) | 2 | (10.0) | 3 | (15.0) | 0 | (0) | 9 | (45.0) | 3 | (15.0) |
| Oklahoma | 5 | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (20.0) | 4 | (80.0) |
| Oregon | 9 | 2 | (22.2) | 4 | (44.4) | 0 | (0) | 0 | (0) | 1 | (11.1) | 2 | (22.2) |
| Pennsylvania | 37 | 3 | (8.1) | 24 | (64.9) | 7 | (18.9) | 4 | (10.8) | 21 | (56.8) | 6 | (16.2) |
| Rhode Island | 1 | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (100.0) | 0 | (0) |
| South Carolina | 10 | 0 | (0) | 2 | (20.0) | 0 | (0) | 0 | (0) | 2 | (20.0) | 6 | (60.0) |
| South Dakota | 1 | 0 | (0) | 0 | (0) | 1 | (100.0) | 0 | (0) | 0 | (0) | 0 | (0) |
| Tennessee | 6 | 1 | (16.7) | 0 | (0) | 1 | (16.7) | 0 | (0) | 5 | (83.3) | 2 | (33.3) |
| Texas | 104 | 4 | (3.8) | 3 | (2.9) | 19 | (18.3) | 0 | (0) | 54 | (51.9) | 29 | (27.9) |
| Utah | 0 | 0 | ... | 0 | ... | 0 | ... | 0 | ... | 0 | ... | 0 | ... |
| Vermont | 1 | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (100.0) | 0 | (0) |
| Virginia | 12 | 2 | (16.7) | 2 | (16.7) | 0 | (0) | 0 | (0) | 5 | (41.7) | 4 | (33.3) |
| Washington | 20 | 1 | (5.0) | 0 | (0) | 3 | (15.0) | 0 | (0) | 2 | (10.0) | 14 | (70.0) |
| West Virginia | 0 | 0 | ... | 0 | ... | 0 | ... | 0 | ... | 0 | ... | 0 | ... |
| Wisconsin | 7 | 2 | (28.6) | 1 | (14.3) | 1 | (14.3) | 1 | (14.3) | 2 | (28.6) | 1 | (14.3) |
| Wyoming | 0 | 0 | ... | 0 | ... | 0 | ... | 0 | ... | 0 | ... | 0 | ... |
| American Samoa ⁵ | 0 | 0 | ... | 0 | ... | 0 | ... | 0 | ... | 0 | ... | 0 | ... |
| Fed. States of Micronesia ⁵ | 1 | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (100.0) |
| Guam ⁵ | 3 | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (33.3) | 2 | (66.7) |
| Marshall Islands ⁵ | 6 | 1 | (16.7) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 5 | (83.3) |
| N. Mariana Islands ⁵ | 0 | 0 | ... | 0 | ... | 0 | ... | 0 | ... | 0 | ... | 0 | ... |
| Puerto Rico ⁵ | 3 | 1 | (33.3) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 2 | (66.7) |
| Republic of Palau ⁵ | 0 | 0 | ... | 0 | ... | 0 | ... | 0 | ... | 0 | ... | 0 | ... |
| U.S. Virgin Islands ⁵ | 0 | 0 | ... | 0 | ... | 0 | ... | 0 | ... | 0 | ... | 0 | ... |

¹Most recent year for which data are available.

²Among patients who were alive at diagnosis, started on treatment and had a duration of treatment >365 days.

³Patient may have more than one reason therapy was extended beyond 12 months (total reasons therapy extended may be greater than total patients with therapy extended).

⁴Excludes New York City.

⁵Not included in U.S. totals.

Note: Ellipses (...) indicate that the percentage cannot be calculated, and the denominator is 0.